Posts by Sandra Ansanay-Alex
Prof. Bloch and Prof. Courtine Honored with the Queen Elizabeth Prize for Engineering 2026
The Queen Elizabeth Prize for Engineering 2026 has been awarded to Jocelyne Bloch, Head of Neurosurgery at the CHUV and professor at the Université de Lausanne, together with Grégoire Courtine, professor at the EPFL. The award recognizes their pioneering work in developing electronic spinal cord stimulation technologies that restore motor functions in people with spinal…
Read MoreEPFL and UNIL Co-Lead Three New National Research Poles for 2026–2029
For the 2026–2029 period, Switzerland has selected three major National Research Poles (PRN/NCCR) involving scientists from the Université de Lausanne and EPFL. These ambitious programmes address some of the most fundamental and urgent scientific challenges: the origins of life, the fight against childhood cancer, and separation sciences. Genesis: understanding the origins of lifeCo-hosted by the…
Read MorePfizer Prize: HUG, UNIL and UNIFR Researchers Awarded
Three Swiss Health Valley research projects have been awarded the Prix Pfizer de la recherche biomédicale 2026, showcasing innovation across cancer immunotherapy, digital health, and personalized medicine. Each project received a CHF 20,000 grant. Personalized cancer vaccine – HUGA research team led by Nicolas Mach, together with Rémi Vernet and Eugenio Fernandez at the HUG…
Read MoreORamaVR Secures $4.5M Late-Seed Funding to Lead theComputational Medical XR Revolution
ORamaVR, the Athens and Geneva-based company the pioneering Computational Medical Extended Reality (CMXR) platform, announced the successful close of a $4.5M seed funding round led by Big Pi Ventures and with additional capital provided by Evercurious VC, both Grece-based technology focused venture capital funds. The funds will be used to expand the company’s product development…
Read MoreMPC Therapeutics launches MitoStem™ to boost CAR-T Cell Durability
The Geneva-based biotech company announces the commercial launch of MitoStem™, a novel T-cell quality enhancer designed to improve the durability and effectiveness of CAR-T therapies through mitochondrial metabolic reprogramming. MitoStem™ increases the proportion of stem cell memory T cells (Tscm), a key immune cell subtype strongly linked to long-lasting therapeutic responses. By reprogramming cellular metabolism,…
Read MoreBioAlps Networking Day 2026
Get your early-bird ticket for the BioAlps Networking Day 2026 on 19 November at Beaulieu Lausanne The Swiss Health Valley 🇨🇭 community comes together once a year to share, connect and push life sciences forward. In 2026, the BioAlps Networking Day lands in Lausanne on 19 November at Palais Beaulieu. The morning will shine a spotlight on Vaud’s thriving life sciences innovation ecosystem.…
Read MoreSamanTree Medical secured €20 million in financing from the European Investment Bank (EIB)
SamanTree Medical, a European leader in surgical imaging innovation, has secured €20 million in financing from the European Investment Bank (EIB). This financing will support the continued development and commercialisation of the Histolog® Scanner in Europe and the United States. This transaction is supported by InvestEU, the EU’s flagship program to mobilize more than €372…
Read MoreSPHN Releases Clinical Data From 800,000 Patients
The Swiss Personalised Health Network has released the metadata of a uniquely rich national clinical dataset, spanning 800,000+ patients and billions of semantically harmonized data points across diagnoses, procedures, labs, medications, vital signs, oncology, and more. Researchers can now easily discover what data exists and how to access it. The Swiss Personalized Health Network (SPHN) is “a…
Read Moreten23 health® and BD Partner to Advance Portable Injection Solutions
ten23 health® has announced a strategic manufacturing partnership with BD to support the commercialization of the BD Libertas™ Wearable Injector, a ready-to-use platform designed for the subcutaneous delivery of high-volume biologic drugs. This collaboration responds to the growing demand for self-administered therapies by offering biopharmaceutical companies a fully integrated solution, combining BD’s injector technology with…
Read MoreTERAPET Announces Partnership With Anzai Medical in Japan
This collaboration represents an important milestone in TERAPET’s international growth strategy and reinforces the company’s mission to make particle therapy safer, smarter, and more adaptive through imaging-driven verification. Anzai Medical Co., Ltd., a leading provider of advanced medical technologies in Japan. Under this agreement, Anzai Medical will serve as Geneva-based medtech company TERAPET’s exclusive distributor in Japan, supporting the introduction and adoption of TERAPET’s flagship platform Qualyscan® in clinical particle therapy workflows at leading centers of excellence nationwide. This collaboration represents an important milestone in TERAPET’s international growth strategy and reinforces the…
Read More